INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) Tuesday reported positive topline results from the Phase 3 BRUIN CLL-314 study evaluating pirtobrutinib versus ibrutinibin in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study met its primary goal of non-inferiority on overall response rate (ORR).
The overall safety profile of pirtobrutinib in the study was consistent with previously reported studies.
'The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally,' the company said in a statement.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
